On April 16, 2018, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab). This approval, identified as BLA 125554 S-58, was granted based on new efficacy data, as indicated by the application details.
Background
Nivolumab, marketed as Opdivo, is a therapeutic agent developed and sponsored by Bristol Myers Squibb. Supplemental applications are a standard regulatory mechanism for existing approved drugs, allowing for updates or expansions to their indications, dosing, or other label information. This specific supplemental application focused on efficacy, suggesting that new clinical evidence supported an expanded or refined use of the drug.
What this means
This supplemental efficacy approval for Opdivo (nivolumab) on April 16, 2018, signifies that the FDA has reviewed and accepted new data supporting the drug's effectiveness in an additional or modified context. Supplemental applications are a common regulatory pathway for pharmaceutical companies to expand the approved uses of an existing drug, introduce new formulations, or update labeling based on post-market data or new clinical trials. For clinicians, this approval indicates that nivolumab is now cleared for an additional or refined indication, allowing for its use in a broader patient population or under different treatment parameters. Researchers may find this development relevant for understanding the evolving landscape of therapeutic applications, while patient advocates can note the potential for expanded treatment options.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-58, concerning Opdivo (nivolumab), was documented on April 16, 2018, on accessdata.fda.gov.